Suppressor-Cell Dysfunction in Systemic Lupus Erythematosus
Open Access
- 1 October 1978
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 62 (4), 789-796
- https://doi.org/10.1172/JCI109190
Abstract
To characterize the cell(s) responsible for the suppressor-cell dysfunction in active systemic lupus erythematosus (SLE), we fractionated blood mononuclear cells into thymus-derived (T), bone marrow-derived (B), and monocyte-depleted populations. Various cell populations from active SLE, inactive SLE, or normals, were activated with Concanavalin A, washed, and then co-cultured with active SLE cells. Soluble immune response suppressor (SIRS) from culture supernates of the activated cells was also used for the possible correction of the suppressor-cell dysfunction. Suppression was tested by enumerating DNA-binding cells by radioautography and by quantitating anti-DNA antibody in culture supernates by radioimmunoassay; and immunoglobulin was tested in cells and supernates by the immunofluorescence and the immunofluor techniques, respectively. Except for the numbers of DNA-binding cells, which were not suppressed, all the other three parameters in co-cultures with cells from active SLE patients were suppressed by Concanavalin A-activated cells (P < 0.001), or by SIRS (P < 0.05) from normals or inactive SLE patients. Concanavalin A-activated autologous or allogeneic active SLE cells and nonactivated cells from active or inactive SLE failed to suppress the various B-cell functions. Nonactivated normal cells suppressed levels of anti-DNA and immunoglobulin in supernates (P < 0.05). In characterizing the cells responsible for the suppressor dysfunction, it was clear from the results that T cells responsive to Concanavalin A activation are deficient in active SLE and fail to generate SIRS. On the other hand, monocytes from active SLE patients are responsive to signals from the activated T cells of normals or inactive SLE donors. Because SIRS suppresses active SLE cells in vitro, it might be considered therapeutically for the in vivo modulation of SLE.Keywords
This publication has 27 references indexed in Scilit:
- Concomitant Presence of Tumor-Specific Cytotoxic and Inhibitor Lymphocytes in Patients with Osteogenic SarcomaNew England Journal of Medicine, 1977
- Prevention of Autoimmunity in Experimental Lupus Erythematosus by Soluble Immune Response SuppressorScience, 1977
- Null cells in peripheral blood of normals and systemic lupus erythematosusClinical Immunology and Immunopathology, 1976
- Suppressor T-cell abnormality in idiopathic systemic lupus erythematosusClinical Immunology and Immunopathology, 1976
- Disordered Immunologic Regulation and AutoimmunityImmunological Reviews, 1976
- Fractionation of cells on a discontinuous Ficoll gradient. Study of subpopulations of human T cells using anti-T-cell antibodies from patients with systemic lupus erythematosus.JCI Insight, 1976
- Identification of DNA-binding lymphocytes in patients with systemic lupus erythematosus.JCI Insight, 1975
- Properties of Primed Suppressor T Cells and their ProductsImmunological Reviews, 1975
- ROLE OF SUPPRESSOR T CELLS IN PATHOGENESIS OF COMMON VARIABLE HYPOGAMMAGLOBULINÆMIAThe Lancet, 1974
- INHIBITORY AND STIMULATORY EFFECTS OF CONCANAVALIN A ON THE RESPONSE OF MOUSE SPLEEN CELL SUSPENSIONS TO ANTIGENThe Journal of Experimental Medicine, 1972